What are the immediate acting and long acting opioids for pain management?

Immediate Acting and Long Acting Opioids for Pain Management

Immediate-release (IR) opioids should be used as first-line treatment for moderate to severe cancer pain, while extended-release/long-acting (ER/LA) opioids should be reserved for around-the-clock pain management after pain control is established with immediate-release formulations. 1

Classification of Opioids

Immediate-Release (Short-Acting) Opioids

• Morphine IR: Oral tablets/solution, 15-30 mg PO every 4-6 hours 2
• Oxycodone IR: 5-15 mg PO every 4-6 hours 2
• Hydromorphone: 2-4 mg PO every 4-6 hours 2
• Oxymorphone: 10-20 mg PO every 4-6 hours 2
• Codeine (often with acetaminophen): 30-60 mg PO every 4-6 hours 2
• Hydrocodone (with acetaminophen): 5-15 mg PO every 4-6 hours 2
• Fentanyl (transmucosal formulations): For breakthrough pain in opioid-tolerant cancer patients 2

Extended-Release/Long-Acting Opioids

• Morphine ER/SR: Twice-daily or once-daily formulations 3
• Oxycodone ER: Twice-daily formulations 1
• Hydrocodone ER: Once-daily formulations 1
• Oxymorphone ER: Twice-daily formulations 1
• Fentanyl transdermal: Patch formulations (72-hour duration) 3
• Buprenorphine transdermal: Patch formulations (7-day duration) 4
• Methadone: Long half-life (8 to >120 hours), requires specialist management 5

Clinical Application

When to Use Immediate-Release Opioids

1. Initial opioid therapy: Always start with immediate-release formulations for titration 1
2. Breakthrough pain: Use IR opioids as rescue medication (typically 10-15% of total daily dose) 3
3. Rapid pain control needed: IV administration for faster titration when severe pain requires urgent relief 3
4. Episodic or unpredictable pain: For "as needed" dosing 3
5. Dose finding: During initiation of opioid therapy to determine appropriate dosage 6

When to Use Long-Acting Opioids

1. After pain control established: Convert to ER/LA formulations after stable dosing achieved with IR opioids 1
2. Stable, continuous pain: For patients requiring around-the-clock analgesia 3
3. Maintenance therapy: After titration with immediate-release formulations 3
4. Improved adherence: Reduced dosing frequency (once or twice daily) 4

Special Considerations

Renal Impairment

• Preferred opioids: Fentanyl and buprenorphine (transdermal or IV) are safest in chronic kidney disease stages 4-5 3
• Avoid or reduce: Morphine should be avoided or used with caution due to accumulation of active metabolites 5

Route of Administration

• Oral route: First choice when possible 3
• Subcutaneous: Simple and effective alternative when oral route not feasible 3
• Intravenous: Consider when subcutaneous administration is contraindicated or rapid pain control needed 3

Clinical Pearls and Pitfalls

Common Pitfalls

1. Starting with long-acting opioids: This increases risk of overdose compared to starting with immediate-release formulations 1
2. Fixed ratio for breakthrough dosing: The conventional one-sixth rule for breakthrough dosing is being challenged; individual titration may be needed 7
3. Inadequate management of side effects: Constipation and nausea are common and may require prophylactic management 3
4. Inappropriate use of transmucosal fentanyl: Should only be used for breakthrough pain in opioid-tolerant cancer patients 2

Important Considerations

1. Regular assessment: Pain intensity and treatment outcomes should be regularly assessed using validated scales 3
2. Around-the-clock dosing: For chronic cancer pain, analgesics should be prescribed on a regular basis, not "as needed" 3
3. Opioid rotation: Consider switching opioids if inadequate analgesia despite dose escalation or unacceptable side effects 3
4. Laxatives: Must be routinely prescribed for prophylaxis and management of opioid-induced constipation 3

Practical Approach to Opioid Selection

1. Assess pain severity:

   • Mild pain: Non-opioid analgesics (NSAIDs, acetaminophen)
   • Moderate pain: Weak opioids or low-dose strong opioids plus non-opioids
   • Severe pain: Strong opioids with or without non-opioids 4

2. Initial opioid selection:

   • Start with immediate-release morphine for moderate to severe pain 3
   • Titrate to effect using regular dosing plus rescue doses for breakthrough pain 3

3. Conversion to long-acting formulations:

   • Once stable dosing established, convert to equivalent dose of long-acting formulation
   • Continue to provide immediate-release formulation for breakthrough pain 3

4. Ongoing management:

   • Regular assessment of pain control and side effects
   • Adjust long-acting dose based on breakthrough medication requirements 3

By following these principles, clinicians can effectively utilize both immediate-acting and long-acting opioids to optimize pain management while minimizing risks.